Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metoclopramide rapidly disintegrating tablet - Salix Pharmaceuticals/Wilmington Pharmaceuticals

Drug Profile

Metoclopramide rapidly disintegrating tablet - Salix Pharmaceuticals/Wilmington Pharmaceuticals

Alternative Names: Metoclopramide-Zydis; METOZOLV ODT

Latest Information Update: 02 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wilmington Pharmaceuticals LLC
  • Developer Salix Pharmaceuticals
  • Class Aminobenzoic acids; Antiemetics; Antineoplastics; Benzamides; Chlorobenzenes; Diethylamines; Gastrokinetics; Phenyl ethers; Radiation-sensitising agents; Radiosensitisers; Small molecules
  • Mechanism of Action Dopamine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diabetic gastroparesis; Gastro-oesophageal reflux

Most Recent Events

  • 01 Apr 2015 Salix Pharmaceuticals has been acquired by Valeant Pharmaceuticals International
  • 09 Sep 2009 Registered for Diabetic gastroparesis in USA (PO)
  • 09 Sep 2009 Registered for Gastro-oesophageal reflux in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top